Second CAR-DC Cell Infusion for Advanced Heart Failure
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old and have been diagnosed with dilated cardiomyopathy (a weakened, enlarged heart)
- You received one infusion of CAR-DC therapy at least 6 months ago, but your heart function has declined back to pre-treatment levels despite the first treatment
- You have severe heart failure symptoms (NYHA Class III–IV, meaning limited or no physical activity without symptoms) and low heart pumping ability (ejection fraction below 35%)
- Your blood counts are healthy enough for the procedure: hematocrit above 30%, lymphocytes above 0.5 × 10⁹/L, and platelets above 60 × 10⁹/L
- You do not have severe kidney disease, liver disease, active infections (including hepatitis B, C, HIV, or syphilis), or severe shock
- You understand the risks and benefits and agree to participate with written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
This trial tests whether injecting lab-grown heart cells into the heart can help people with heart failure whose heart pumps less than 40% of normal. It may help improve heart function and reduce symptoms.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.